Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 48.44 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 37.40 | Oscillator | Neutral |
| Williams %R (14) | -71.88 | Oscillator | Neutral |
| MACD (12, 26, 9) | -0.09 (Hist -0.05) | Oscillator | Strong Sell |
| Average Directional Index (14) | 15.94 (+DI 24.3 / -DI 20.9) | Trend | Neutral |
Current price $9.18
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 16, 26 |
| EMA 20 | 9.38 | MA | Sell |
| SMA 20 | 9.66 | MA | Strong Sell |
| EMA 50 | 9.24 | MA | Sell |
| SMA 50 | 9.34 | MA | Sell |
| SMA 200 | 6.30 | MA | Strong Buy |
| Keybanc |
| maintain |
| Overweight |
| Overweight |
| Oct 12, 26 | JP Morgan | maintain | Overweight | Overweight |
| Oct 12, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Sep 23, 26 | Needham | maintain | Buy | Buy |
| Sep 8, 26 | BTIG | maintain | Buy | Buy |
| Aug 12, 26 | Needham | maintain | Buy | Buy |
| Aug 12, 26 | BTIG | maintain | Buy | Buy |
| Jul 2, 26 | Truist Securities | maintain | Buy | Buy |
| Jun 25, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| 10-Q | Aug 11, 2026 | 2026-08-11 16:08:50 | View |
| 8-K | Aug 11, 2026 | 2026-08-11 16:06:14 | View |
| 4 | Aug 7, 2026 | 2026-08-07 16:54:11 | View |
| 3 | Aug 7, 2026 | 2026-08-07 16:53:52 | View |
| 4 | Jul 6, 2026 | 2026-07-06 16:06:13 | View |
| 4 | Jun 26, 2026 | 2026-06-26 16:21:34 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Oct 12, 26 | Mcclain Sean | director, officer: Chief Executive Officer | F-InKind | 23,293 @ $10.16 | $236.7K |
| Oct 12, 26 | Bedrick Todd | officer: SVP, CAO | F-InKind | 22,325 @ $10.16 | $226.8K |
| Oct 12, 26 | Jonasson Zachariah | officer: CFO / CBO | F-InKind | 387 @ $10.16 | $3.93K |
| Aug 31, 26 | Jonasson Zachariah | officer: CFO / CBO | F-InKind | 8,320 @ $8.71 | $72.47K |
| Mar 3, 26 | Somaratne Ransi Mudalinayake | officer: CMO, Head of R&D | A-Award | 650,000 @ $2.57 | $1.67M |
| Aug 3, 26 | Somaratne Ransi Mudalinayake | officer: CMO, Head of R&D | A-Award | 383,000 @ $7.93 | $3.04M |
| Mar 3, 26 | Somaratne Ransi Mudalinayake | officer | 0 | — | |
| Jun 30, 26 | Szela Mary T | director | P-Purchase | 12,900 @ $11.54 | $148.9K |
Stock news · updated daily
VANCOUVER, Wash. and NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the company will report business updates and financial and operating results for the third quarter 2026 before market open on Thursday, November 12, 2026.
Black Diamond Therapeutics (NASDAQ: BDTX - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Insider and Institutional Ownership 95.5% of Black
Phase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP) Anticipated initiation of Phase 2 trial in mid-2027 VANCOUVER, Wash. and NEW YORK, Sept.
Silence Therapeutics (NASDAQ: SLN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends and risk. Risk and Volatility Silence Therapeutics has a beta
Valneva (NASDAQ: VALN - Get Free Report) and Absci (NASDAQ: ABSI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation. Profitability This table compares Valneva and Absci's net margins,
Absci Corporation (ABSI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Absci Corporation is upgraded to “Buy” following positive interim Phase 1 data for ABS-201 in androgenetic alopecia [AGA]. ABS-201 demonstrated an excellent PK profile, enabling infrequent dosing [2–3 injections per 6 months] and strong safety/tolerability in SAD cohorts. Upcoming catalysts include 13-week interim proof-of-concept data in 2H 2026 and 26-week topline results in early 2027 for ABS-201 in AGA.
Bank of America Corp DE raised its holdings in Absci Corporation (NASDAQ: ABSI) by 55.2% in the undefined quarter, according to its most recent 13F filing with the SEC. The fund owned 487,193 shares of the company's stock after acquiring an additional 173,361 shares during the period. Bank of America Corp DE owned
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 11, 2026 | -0.19 | -0.18 | Beat 5.8% | $300.0K |
| May 7, 2026 | -0.20 | -0.19 | Beat 5.0% | $215.0K |
| Mar 24, 2026 | -0.16 | -0.23 | Miss -43.8% | $650.0K |
| Nov 12, 2025 | -0.19 | -0.20 | Miss -5.3% | $378.0K |
| Aug 12, 2025 | -0.19 | -0.24 | Miss -26.3% | $593.0K |
| May 13, 2025 | -0.23 | -0.21 | Beat 8.7% | $1.18M |
TTM vs. 5-year historical average (annual ratios)
| Metric | ABSI | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -11.5x | -3.9x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -11.5x | EPS est. -0.80 | In line |
| Price / Book | 5.9x | 1.8x | Elevated |
| Price / Sales | 1009.2x | 98.8x | Elevated |
| EV / EBITDA | -13.4x | -4.2x | Elevated |
| Return on equity | -59.2% | — | Weak |
| Gross margin | -255.9% | -817.2% | Below hist. |
| Debt / Equity | 0.01 | 0.06 | Conservative |
| Piotroski / Altman Z | 4/9 | Z 38.13 | Safe zone |
Discounted cash flow model